Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jan;73(2):217–221. doi: 10.1038/bjc.1996.38

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.

K Matsui 1, M Fukuoka 1, M Takada 1, Y Kusunoki 1, T Yana 1, K Tamura 1, T Yoshida 1, K Iida 1, T Hirashima 1, H Tsukada 1, S Ushijima 1, H Miyawaki 1, N Masuda 1
PMCID: PMC2074303  PMID: 8546909

Abstract

Despite recent advances in control of acute emesis following cisplatin-based chemotherapy regimens, delayed emesis remains a significant cause of treatment-related morbidity and factors associated with delayed emesis have not yet been evaluated. A prospective randomised trial was conducted to compare the efficacy and toxicity of granisetron, dexamethasone plus prochlorperazine with granisetron alone in controlling cisplatin-induced delayed emesis and to identify the important factors that influence its occurrence and severity. Seventy cisplatin-naive patients with inoperable solid tumors participated in the trial. Patients who received 80 mg m-2 or 100 mg m-2 of cisplatin were randomly assigned to receive either granisetron 40 micrograms kg-1 intravenously (i.v.) on day 1, dexamethasone 20 mg i.v. on days 2 and 3 and prochlorperazine 5 mg orally thrice daily on days 1-5 or granisetron 40 micrograms kg-1 i.v. on day 1 alone. There was no difference in their acute antiemetic efficacy. A combination regimen was more effective than granisetron alone in preventing delayed symptoms, with superior rates of complete plus major responses of 77% vs 51% (P = 0.0460). Treatment arm was the only determinant factor for the occurrence of delayed emesis (P = 0.0101).

Full text

PDF
217

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chevallier B. The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. Br J Cancer. 1993 Jul;68(1):176–180. doi: 10.1038/bjc.1993.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cunningham D., Hawthorn J., Pople A., Gazet J. C., Ford H. T., Challoner T., Coombes R. C. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet. 1987 Jun 27;1(8548):1461–1463. doi: 10.1016/s0140-6736(87)92208-2. [DOI] [PubMed] [Google Scholar]
  3. Gandara D. R., Harvey W. H., Monaghan G. G., Perez E. A., Stokes C., Bryson J. C., Finn A. L., Hesketh P. J. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol. 1992 Aug;19(4 Suppl 10):67–71. [PubMed] [Google Scholar]
  4. Gralla R. J., Itri L. M., Pisko S. E., Squillante A. E., Kelsen D. P., Braun D. W., Jr, Bordin L. A., Braun T. J., Young C. W. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981 Oct 15;305(16):905–909. doi: 10.1056/NEJM198110153051601. [DOI] [PubMed] [Google Scholar]
  5. Hainsworth J. D., Hesketh P. J. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin Oncol. 1992 Dec;19(6 Suppl 15):14–19. [PubMed] [Google Scholar]
  6. Hamik A., Peroutka S. J. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307–310. doi: 10.1007/BF00304763. [DOI] [PubMed] [Google Scholar]
  7. Herrstedt J., Sigsgaard T., Boesgaard M., Jensen T. P., Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med. 1993 Apr 15;328(15):1076–1080. doi: 10.1056/NEJM199304153281502. [DOI] [PubMed] [Google Scholar]
  8. Jantunen I. T., Muhonen T. T., Kataja V. V., Flander M. K., Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. Eur J Cancer. 1993;29A(12):1669–1672. doi: 10.1016/0959-8049(93)90101-k. [DOI] [PubMed] [Google Scholar]
  9. Joss R. A., Dott C. S. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group. Eur J Cancer. 1993;29A Suppl 1:S22–S29. doi: 10.1016/s0959-8049(05)80256-4. [DOI] [PubMed] [Google Scholar]
  10. Kaizer L., Warr D., Hoskins P., Latreille J., Lofters W., Yau J., Palmer M., Zee B., Levy M., Pater J. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 May;12(5):1050–1057. doi: 10.1200/JCO.1994.12.5.1050. [DOI] [PubMed] [Google Scholar]
  11. Kaye S. B., Khayat D., Aapro M., Diehl V. Who should receive a 5-HT3 antagonist? Lancet. 1992 Oct 31;340(8827):1107–1108. doi: 10.1016/0140-6736(92)93138-d. [DOI] [PubMed] [Google Scholar]
  12. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B., O'Connell J. P., Wertheim M. S., Kelsen D. P. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985 Oct;3(10):1379–1384. doi: 10.1200/JCO.1985.3.10.1379. [DOI] [PubMed] [Google Scholar]
  13. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Cirrincione C., Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989 Jan;7(1):108–114. doi: 10.1200/JCO.1989.7.1.108. [DOI] [PubMed] [Google Scholar]
  14. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Kelsen D. P., Reilly L. K., Groshen S., Bosl G. J., Kalman L. A. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer. 1985 Feb 1;55(3):527–534. doi: 10.1002/1097-0142(19850201)55:3<527::aid-cncr2820550310>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  15. Kris M. G., Tyson L. B., Gralla R. J., Clark R. A., Allen J. C., Reilly L. K. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med. 1983 Aug 18;309(7):433–434. doi: 10.1056/nejm198308183090718. [DOI] [PubMed] [Google Scholar]
  16. Louvet C., Lorange A., Letendre F., Beaulieu R., Pretty H. M., Courchesne Y., Neemeh J. A., Monte M., Latreille J. Acute and delayed emesis after cisplatin-based regimen: description and prevention. Oncology. 1991;48(5):392–396. doi: 10.1159/000226966. [DOI] [PubMed] [Google Scholar]
  17. Moreno I., Rosell R., Abad A., Barnadas A., Carles J., Ribelles N., Solano V., Font A. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer. 1992;28A(8-9):1344–1347. doi: 10.1016/0959-8049(92)90515-4. [DOI] [PubMed] [Google Scholar]
  18. Roila F., Tonato M., Cognetti F., Cortesi E., Favalli G., Marangolo M., Amadori D., Bella M. A., Gramazio V., Donati D. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991 Apr;9(4):675–678. doi: 10.1200/JCO.1991.9.4.675. [DOI] [PubMed] [Google Scholar]
  19. Von Hoff D. D., Schilsky R., Reichert C. M., Reddick R. L., Rozencweig M., Young R. C., Muggia F. M. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527–1531. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES